Neovascularization has recently been used as a new treatment for severe ischemic disease. We tried to induce therapeutic neovascularization by autologous bone marrow cell implantation (BMCI) in eight selected patients with chronic peripheral arterial disease (PAD), in whom traditional treatments had failed. Improvement of subjective symptoms was seen in seven patients after treatment. Of three limbs with toe or finger ulceration, complete healing was achieved in two, while the other one became less severe after treatment. No relative toxicity was observed in any of the patients. BMCI might be a feasible treatment for selected patients with chronic PAD. 747 748 ESATO ET AL.
INTRODUCTION
icine. Patients with chronic PAD were selected for BMCI treatment on the basis of the following criteria: Much attention has recently been focused on neovas-1) their subjective symptoms remained unchanged or cularization as a new treatment for severe ischemic disshowed deterioration after at least 3 months of continueases unable to be controlled by medication, catheter ous and regular medical treatment; 2) there were no indiintervention, or bypass grafting. Several methods have cations for surgical bypass or catheter intervention; 3) been used to induce therapeutic angiogenesis (2, 5, (8) (9) (10) .
no other therapy was suitable. Informed consent was ob-Bone marrow cells contain various kinds of primitive tained from all the patients enrolled in this study. cells that can differentiate into endothelial cells and se-Collection and Implantation of Autologous Bone crete several growth factors (1, 3) , and it has been dem-Marrow Cells onstrated that autologous bone marrow cell implantation Bone marrow fluid (50-600 ml) was collected from (BMCI) can induce therapeutic angiogenesis and imthe iliac bone under general anesthesia. The harvested prove deteriorated physical function in ischemic heart bone marrow fluid was diluted with heparinized RPMIand hindlimb models (4,6,7). After confirming the safety 1640 (Nikken Bio Medical Laboratory, Kyoto, Japan), of this new therapy in animal models, we started conthen poured into a sterile bag from a Bone Marrow Colducting a clinical trial in September 1999. To date, a lection Kit (Baxter). The patients were allowed to recollective nine limbs in eight patients with chronic pecover from the general anesthesia after the bone marrow ripheral arterial disease (PAD) have been given BMCI fluid had been collected. A mononuclear cell-rich fracas a single treatment. We report herein our preliminary tion of bone marrow cells was separated from the bone results of using this new treatment. marrow fluid using the COBE Spectra Apheresis System (Gambro). The separated bone marrow mononuclear PATIENTS AND METHODS cells were resuspended in RPMI-1640 medium and ad-Patient Selection justed to 2 × 10 8 to 2 × 10 9 cells/ml in concentration according to the number of cells harvested. Following the This clinical trial was approved by the Medical Eth-IV administration of a mild anesthetic agent such as ics Committee of Yamaguchi University School of Med-butorphanol tartrate, patients were given the BMCI one patient and no change in symptoms in one patient, but without any change in ABI or collateral develop-treatment. The target of the BMCI treatment was selected as the most ischemic area with poor collateral ment. Thereafter, we increased the cell number to 2-6 × 10 8 cells/point for injection. All four ischemic limbs in vessels, as judged by thermography, TCPO 2 , and angiography. Cells were injected intramuscularly to a depth three patients given 2 × 10 8 cells/point for injection showed improvement in subjective symptoms by 4 of about 5-10 mm using a 1-ml syringe and a 26-gauge needle. The injection was delivered at about 3-cm inter-weeks, but one of the three patients remained unchanged 1 year after treatment. Two of the three patients showed vals, and each point was injected with 0.1 ml of adjusted bone marrow cell solution. The number of total cells an increase in the local skin temperature of ischemic limbs on thermography ( Fig. 1A) . Furthermore, the de-collected limited the number of injection points in each patient.
velopment of new collateral vessels was seen on angiogram 4 weeks after treatment in two of the three patients To exclude any influence of drug administration, patients were not given any drug except these anticoagu- (Fig. 1B) . The remaining three limbs in three patients with ulceration of the toe or fingers were injected with lants and platelet inhibitors used routinely before BMCI treatment. No patients were given any other treatment, 6 × 10 8 cells/point, resulting in complete healing of the ulceration in two patients and improvement of ulceration or supplemented with any new drugs during the entire follow-up period.
in the other patient 4 weeks after treatment ( Fig. 2) . No complications were experienced by any of the pa-Evaluation of the Curative Effect and Safety tients who underwent BMCI treatment. Moreover, there All patients were assessed at 1 and 12 months after was no sign of any systemic or local toxicity related treatment. We asked about their subjective symptoms to the treatment, such as systemic fever, anemia, local and measured local skin temperature by thermography hematoma, local edema, or local fever in the acute phase at each follow-up point. Angiography was performed to after the BMCI treatment. No anemia, local calcificadetect the development of collateral vessels 4 weeks tion, or scleroma in the injection area developed in any after the treatment. The ankle-branchial index (ABI), a of these patients during 1 year of follow-up. ratio of the ankle pressure to the arm pressure (normally DISCUSSION in the range of 1.1-1.2), was measured to estimate the recovery of perfusion in the ischemic limbs at 1 and 12
All of the patients involved in this clinical trial had months after treatment.
received a number of traditional forms of treatment, in-To detect the possibility of systemic and local toxiccluding repeated surgical bypass or long-term medicaity related to BMCI treatment, blood examinations, chest tion, that had failed to control their subjective symptoms X-rays, and ECGs were also done at each follow-up satisfactorily. However, seven of eight patients showed point.
an improvement of their subjective symptoms after BMCI, which was performed as a single treatment and without RESULTS any additional drugs. Furthermore, six of the nine ischemic limbs showed an increase in Fontaine class (Table  Since September 1999, we performed BMCI treatment as a single therapy in a collective nine ischemic 1) and three showed an increase in local skin temperature on thermography. The three patients with ulceration limbs in eight patients with chronic PAD ( Table 1 ). The diagnoses were: arteriosclerosis obliterans (ASO) in four of the toes or fingers showed complete healing or improvement in ulceration 4 weeks after treatment. The limbs of four patients and thromboangiitis obliterans (TAO) in five limbs of four patients. All of these pa-preliminary results of our clinical trial revealed that BMCI treatment might be a feasible method of relieving tients had previously been treated with medication or surgical bypass. Although continuous and regular tradi-the subjective symptoms of selected patients with PAD, in whom traditional treatments have failed. tional treatments were given, the subjective symptoms in all these patients remained unchanged or showed de-Only two of eight patients showed the development of new collateral vessels on angiogram. Because our an-terioration at least 3 months before they were selected for BMCI treatment. No patient was given any other giogram is limited to finding vessels more than 200 nm in diameter, it is possible that angiogenic microvessels treatment, including new drugs or physiotherapy, within the first 4 weeks after the BMCI treatment.
were not shown on angiogram. We considered that the improvement of clinical symptoms in these patients had The target areas for BMCI treatment were situated in the calf in four limbs of four patients with ASO and in resulted from the induction of angiogenesis by the BMCI treatment. According to previous observations in the foot or hand in five limbs of four patients with TAO. The number of cells injected was 2 × 10 7 cells/point in animal models, bone marrow cells produce growth factors and contain endothelial progenitor cells that partici-the first two patients, resulting in relief of rest pain in pate in vascular formation in ischemic tissue (1, 3, 4, 7) . number dependent. Furthermore, we cannot conclude the optimal cell number for BMCI treatment because We speculate that the mechanisms for inducing therapeutic neovascularization by the BMCI treatment in this only nine limbs of eight patients were included in the present study. clinical trial could be related to both the production of angiogenic growth factors and the endothelial differenti-No systemic or local toxicity related to BMCI treatment was found in any of these patients in the acute or ation from these implanted bone marrow cells in ischemic limbs. chronic phases. Moreover, both the clinical outcomes and our detailed investigations in rats and dogs (data not No increase in skin temperature or any new collateral vessels were seen in the two patients injected with 2 × shown) indicate that BMCI treatment should be safe. The added advantages of this treatment lie in its simplic-10 7 cells/point after treatment. Conversely, it is interesting that the development of new collateral vessels was ity in a clinical trial. The present study was limited in that it was an open-seen on angiogram and an increase in local skin temperature was seen on thermography in three of the four is-label trial involving a small number of patients. The posttreatment evaluation was also limited in an open-chemic limbs given the higher number of bone marrow cells (2 × 10 8 cells/point), and that ulceration completely label trial by these conventional methods of angiography and thermography. Further extension of clinical trials, healed or improved in patients given an injection of 6 × 10 8 cells/point. The outcome of BMCI treatment seems including a placebo treatment control group, is required for confirming the safety and efficacy of BMCI treat-to have been improved by increasing the number of cells injected, even though we cannot provide any evidence ment. We plan to give BMCI as a single treatment in total of about 10 selected patients, and then confirm the that the angiogenic potency of BMCI treatment is cell 
